131 related articles for article (PubMed ID: 3948162)
1. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion.
Ip MM; Sylvester PW; Schenkel L
Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162
[TBL] [Abstract][Full Text] [Related]
2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
3. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma.
Ip MM; Milholland RJ; Rosen F
Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of prostaglandin F2 alpha on the growth of a hormone-dependent rat mammary tumor.
Jubiz W; Frailey J; Smith JB
Cancer Res; 1979 Mar; 39(3):998-1000. PubMed ID: 427787
[TBL] [Abstract][Full Text] [Related]
6. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
7. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
8. Short-term primary culture of rat prostate tumor epithelial cells on reconstituted basement membrane as a useful in vitro model to assess drug action on prostatic cancer: efficacy of the thiazolidinedione derivative CGP 19984.
Shea WK; Black J; Ip MM
Prostate; 1989; 15(2):157-70. PubMed ID: 2798233
[TBL] [Abstract][Full Text] [Related]
9. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
10. Dichotomous effects of tamoxifen on a transplantable rat mammary tumor.
Ip MM; Milholland RJ; Rosen F; Kim U
Cancer Res; 1981 Mar; 41(3):984-8. PubMed ID: 7459886
[TBL] [Abstract][Full Text] [Related]
11. Effects of the thiazolidinedione derivative CGP 19984 on growth and endocrine function of the MtT-W10 transplantable mammosomatotropic pituitary tumor in female rats.
Sylvester PW; Utz PJ; Ip MM
Int J Cancer; 1988 Aug; 42(2):289-94. PubMed ID: 3403072
[TBL] [Abstract][Full Text] [Related]
12. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor.
Lokeshwar BL; Hurkadli KS; Sheth AR; Block NL
Cancer Res; 1993 Oct; 53(20):4855-9. PubMed ID: 8402673
[TBL] [Abstract][Full Text] [Related]
13. Effects of 17 beta-estradiol and medroxyprogesterone acetate upon MtTW15 mammosomatotropic pituitary tumor growth and hormone production in male and female rats.
Winneker RC; Parsons JA
Cancer Res; 1981 May; 41(5):1772-7. PubMed ID: 7214344
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
15. Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Houjou T; Wada T; Yasutomi M
Clin Ther; 1993; 15(1):137-47. PubMed ID: 8458043
[TBL] [Abstract][Full Text] [Related]
16. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
18. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
20. Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor.
Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan PD
Clin Physiol Biochem; 1992; 9(2):47-50. PubMed ID: 1284786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
